| Guidance for Transitioning Among Anticoagulants | AACN Advanced Critical Care | 2019 |
| Thromboprophylaxis in Orthopedic Surgery | | 2016 |
| Profile of patients diagnosed with acute venous thromboembolism in routine practice according to age and renal function: RE-COVERY DVT/PE study | Journal of Thrombosis and Thrombolysis | 2021 |
| Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case-control study | British Journal of Clinical Pharmacology | 2020 |
| Drug-Drug Interactions with Direct Oral Anticoagulants | Clinical Pharmacokinetics | 2020 |
| Cardiovascular Risk Management and Hepatitis C: Combining Drugs | Clinical Pharmacokinetics | 2019 |
| A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4 | Clinical Pharmacokinetics | 2019 |
| Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants | Journal of Thrombosis and Haemostasis | 2019 |
| How Does "Regulatory Practice" Create Discrepancies in Drug Label Information Between Asian and Western Countries? Different Label Information for Direct Oral Anticoagulants Approved in the United States, Europe, Korea, and Japan | Therapeutic Innovation and Regulatory Science | 2019 |
| Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report | Chest | 2018 |
| Oral Anticoagulation in Patients With Liver Disease | Journal of the American College of Cardiology | 2018 |
| Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation | Thrombosis Journal | 2018 |
| Management of Dabigatran-associated bleeding in two elderly patients with acute renal failure | Annals of Hematology | 2018 |
| Drug interaction as a predictor of direct oral anticoagulant drug levels in atrial fibrillation patients | Journal of Thrombosis and Thrombolysis | 2018 |
| Hepatotoxicity of New Oral Anticoagulants | Rational Pharmacotherapy in Cardiology | 2018 |
| Use of oral anticoagulants in German nursing home residents: drug use patterns and predictors for treatment choice | British Journal of Clinical Pharmacology | 2018 |
| Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians | Journal of Thrombosis and Haemostasis | 2018 |
| Direct-acting oral anticoagulant drug level monitoring in clinical patient management | Journal of Thrombosis and Thrombolysis | 2018 |
| Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting | Oncologist | 2018 |
| Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban | Current Medical Research and Opinion | 2018 |
| Direct oral anticoagulant use and risk of perioperative bleeding: Evidence of absence or absence of evidence? | Research and Practice in Thrombosis and Haemostasis | 2018 |
| Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury | Journal of the American College of Cardiology | 2018 |
| Haematological factors in the management of adult epistaxis: systematic review | Journal of Laryngology and Otology | 2017 |
| Direct oral anticoagulant considerations in solid organ transplantation: A review | Clinical Transplantation | 2017 |
| Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis | British Journal of Clinical Pharmacology | 2017 |
| Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs | European Journal of Clinical Pharmacology | 2017 |
| Dabigatran and vitamin K antagonists' use in naïve patients with non-valvular atrial fibrillation: a cross-sectional study of primary care-based electronic health records | European Journal of Clinical Pharmacology | 2017 |
| Anti-thrombotic therapy for atrial fibrillation in patients with chronic kidney disease: Current views | Hemodialysis International | 2017 |
| Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future: Views from a workshop at the European Medicines Agency (EMA) | European Heart Journal - Cardiovascular Pharmacotherapy | 2017 |
| Direct oral anticoagulants and cardiovascular prevention in patients with nonvalvular atrial fibrillation | Expert Opinion on Pharmacotherapy | 2017 |
| Medication errors involving anticoagulants: Data from the Danish patient safety database | Pharmacology Research and Perspectives | 2017 |
| Perioperative management of patients on direct oral anticoagulants | Thrombosis Journal | 2017 |
| Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin | Journal of Thrombosis and Haemostasis | 2017 |
| Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment | International Journal of Hematology | 2017 |
| Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation | Journal of Thrombosis and Thrombolysis | 2017 |
| Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants | Critical Care | 2017 |
| Novel oral anticoagulants and the 73rd anniversary of historical warfarin | Journal of the Saudi Heart Association | 2016 |
| Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome | Rheumatology | 2016 |
| Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants | Cardiovascular Drugs and Therapy | 2016 |
| Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting | Thrombosis Journal | 2016 |
| Drug Treatment of Venous Thromboembolism in the Elderly | Drugs and Aging | 2016 |
| The Effect of Cardiopulmonary Bypass on Dabigatran Levels | Journal of Cardiothoracic and Vascular Anesthesia | 2016 |
| Managing novel orally administered anticoagulants in patients undergoing urogynaecological surgery | International Urogynecology Journal | 2016 |
| Glomerular filtration rate assessed by using creatinine and cystatin in patients treated with dabigatran | Rivista Italiana Della Medicina Di Laboratorio | 2016 |
| Spotlight on advances in VTE management: CALLISTO and EINSTEIN CHOICE | Thrombosis and Haemostasis | 2016 |
| The use of novel oral anticoagulants in cancer patients with venous thromboembolism | Seminars in Oncology | 2016 |
| Drug-drug interactions of non-vitamin K oral anticoagulants | Expert Opinion on Drug Metabolism and Toxicology | 2016 |
| Use of direct oral anticoagulants with regional anesthesia in orthopedic patients | Journal of Clinical Anesthesia | 2016 |
| Benefits of once-daily dosing with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation | European Heart Journal Supplements | 2016 |
| Once-daily rivaroxaban for long-term stroke prevention in patients with atrial fibrillation | European Heart Journal Supplements | 2016 |
